• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Microorganisms . Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2

tetano

Editor, Senior Moderator
Microorganisms


. 2021 Jun 21;9(6):1340.
doi: 10.3390/microorganisms9061340.
Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2


Jean-Louis Bayart[SUP] 1 [/SUP], Laure Morimont[SUP] 2 3 [/SUP], Mélanie Closset[SUP] 4 [/SUP], Grégoire Wieërs[SUP] 5 [/SUP], Tatiana Roy[SUP] 1 [/SUP], Vincent Gerin[SUP] 1 [/SUP], Marc Elsen[SUP] 6 [/SUP], Christine Eucher[SUP] 6 [/SUP], Sandrine Van Eeckhoudt[SUP] 7 [/SUP], Nathalie Ausselet[SUP] 8 [/SUP], Clara David[SUP] 3 [/SUP], François Mullier[SUP] 4 [/SUP], Jean-Michel Dogné[SUP] 2 [/SUP], Julien Favresse[SUP] 2 6 [/SUP], Jonathan Douxfils[SUP] 2 3 [/SUP]



Affiliations

Abstract

Background: Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine.
Methods: Blood samples from 231 subjects were collected before and 14, 28, and 42 days following coronavirus disease 2019 (COVID-19) vaccination with BNT162b2. Anti-spike receptor-binding-domain protein (anti-Spike/RBD) immunoglobulin G (IgG) antibodies were measured at each time-point. Impact of age, sex, childbearing age status, hormonal therapy, blood group, body mass index and past-history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were assessed by multivariable analyses.
Results and conclusions: In naïve subjects, the level of anti-Spike/RBD antibodies gradually increased following administration of the first dose to reach the maximal response at day 28 and then plateauing at day 42. In vaccinated subjects with previous SARS-CoV-2 infection, the plateau was reached sooner (i.e., at day 14). In the naïve population, age had a significant negative impact on anti-Spike/RBD titers at days 14 and 28 while lower levels were observed for males at day 42, when corrected for other confounding factors. Body mass index (BMI) as well as B and AB blood groups had a significant impact in various subgroups on the early response at day 14 but no longer after. No significant confounding factors were highlighted in the previously infected group.

Keywords: BMI; BNT162b2; SARS-CoV-2; age; antibody; blood-group; gender; kinetic; serology; vaccine.
 
Back
Top Bottom